15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Cardiff Oncology Inc, 1 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a hold consensus. The target range is very wide, $2.00 to $10.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.00 sits 623% above the current $0.83. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Hold
Strong Buy00%
Buy125%
Hold375%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Cardiff Oncology Inc.
As of Jul, 1 of 4 firms rate CRDF a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRDF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.20 – $-0.13 · 6 analysts · -1% YoY
Next period, 6 analysts expect Cardiff Oncology Inc to earn $-0.17 a share (range $-0.20 – $-0.13), versus $-0.17 a year earlier. Full-year consensus is $-0.69, growing to $-0.81 the year after.
REVENUE · NEXT QUARTER
$67.2K
Range $0 – $150.0K · 6 analysts · -44% YoY
Revenue is expected to reach $67.2K (range $0 – $150.0K), -44.0% year-over-year. Full-year consensus is $229.6K, rising to $189.3K next year.
Top analysts covering Cardiff Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRDF.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Hold
No targeton CRDF
Overall win rate
38%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #219
Buy
$10.00+1104.5% to target
Overall win rate
41%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$13.00+1465.9% to target
Overall win rate
37%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$6.00+622.7% to target
Overall win rate
29%
+ Follow
#5
RL
Robert LeBoyer
Noble Financial
Buy
$12.00+1345.4% to target
Coverage
—
+ Follow
CRDF stock forecast FAQ
What is CRDF's average 12-month price target?+
The 2 analysts with a live target average $6.00 for Cardiff Oncology Inc over the next 12 months, ranging from a $10.00 high to a $2.00 low.
Is CRDF stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 4 analyst ratings, 1 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRDF?+
The Street-high target is $10.00, and the Street-low is $2.00 (Craig-Hallum). The average of all 2 active targets is $6.00.
How many Wall Street analysts cover CRDF?+
4 analysts have an active rating on Cardiff Oncology Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRDF?+
Among analysts who currently cover CRDF, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Hold.
What is Cardiff Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.20 – $-0.13) across 6 analysts. Full-year EPS is projected at $-0.69, rising to $-0.81 the following year.
How much revenue is Cardiff Oncology Inc expected to report next quarter?+
Consensus revenue is $67.2K (range $0 – $150.0K). Full-year revenue is projected at $229.6K, growing to $189.3K next year.
Have analysts been upgrading or downgrading CRDF lately?+
As of Jul, 1 of 4 firms rate CRDF a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRDF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
